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Abstract
The nature of host-virus interactions in hepatitis B virus infection is incompletely understood. Since soluble factors, e.g.,
cytokines and metals, may exacerbate liver injury in chronic hepatitis, we considered that defining the effects of receptor-
mediated signaling upon viral replication will be significant. Consequently, we studied effects of iron or TGF-b-induced TGF-
b/BMP signaling in the HepG2 2.2.15 cell model of hepatitis B virus replication. We found iron and TGF-b increased hepcidin
mRNA expression or TGF-b receptor kinase activity, respectively, which indicated that 2.2.15 cells responded appropriately
to these substances. However, iron increased but TGF-b decreased hepatitis B virus mRNA and DNA expression. TGF-b
induced expression at the mRNA level of multiple TGF-b/BMP pathway genes. This change was not observed in iron-treated
cells. On the other hand, presence of SMAD proteins in iron or TGF-b-treated cells, including of SMAD4, did confirm
convergence of TGF-b/BMP signaling pathways under these conditions. Since transcription factors in TGF-b/BMP signaling
pathways could not have directly targeted hepatitis B virus itself, we studied whether iron or TGF-b exerted their effects
through alternative mechanisms, such as by involvement of antiviral cellular microRNAs. We discovered cellular microRNA
expression profiles were significantly different in iron or TGF-b-treated cells compared with untreated control cells. In many
cases, exposure to iron or TGF-b changed microRNA expression in opposite directions. Introduction in cells of sequences
representing such differentially expressed microRNAs, e.g., hsa-miR-125a-5p and -151-5p, even reproduced effects on virus
replication of iron- or TGF-b. We surmised that TGF-b/BMP pathway members, i.e., SMADs, likely governed iron or TGF-b-
induced microRNA expression. Iron may have mediated Drosha/DGCR8/heme-mediated processing of microRNAs. In turn,
cellular microRNAs regulated replication of hepatitis B virus in iron or TGF-b-treated cells. This knowledge should advance
studies of mechanisms in viral-host interactions, hepatic injury, and therapeutic developments for hepatitis B.
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Introduction
Intra- and extracellular soluble signaling molecules are involved
in hepatitis virus replication but these interactions are not well
understood. For instance, inflammatory cytokines affect hepatitis B
virus (HBV) replication by recruiting more than one signaling
pathways. Among these, interleukins (e.g., IL12, IL18) may inhibit
HBV replication, including with recruitment of interferon (IFN)-c
released from NK or T cells [1,2]. Interferon-a has widely been
used for treating HBV with JAK/STAT signaling serving
intermediary roles [3]. The role of these intracellular signaling
pathways in transducing antiviral effects of interferon is far from
complete and new information is still emerging [4]. Other cytokine
pathways off note include tumor necrosis factor-a, which
suppressed HBV replication [5]. Also, transforming growth factor
(TGF)-b inhibited HBV replication [6], presumably with involve-
ment of TGF-b signaling through SMAD-2 and -3 [7]. The
canonical TGF-b signaling pathways involve SMADs -2 and -3
compared with bone morphogenetic protein (BMP) signaling via
SMAD-1, -5, and -8. Nonetheless, after activation of TGF-b-o r
BMP receptors leads to heteromeric complexing between SMADs,
followed by engagement with the common-mediator, SMAD-4,
which is required and sufficient for regulation of nuclear
transcription, and in this way, brings together TGF-b/BMP
signaling pathways. How these diverse intracellular signaling
pathways may regulate replication of HBV (or other viruses) is yet
to be clarified.
Disease-modifying cofactors, e.g., iron, are capable of altering
HBV replication. In clinical studies, elevated hepatic iron content
has been associated with higher prevalence of HBV infection [8],
as well as worse outcomes in chronic hepatitis [9]. However, the
molecular basis by which iron may alter HBV replication is
unknown. Recently, hepatic release of hepcidin was found to be
important in iron homeostasis, by decreasing intestinal iron
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39276absorption as well as hepatic iron uptake. As hepcidin exerts its
intracellular effects by TGF-b/BMP signaling [10], a relationship
emerged between this molecule and other intracellular mediators
of cytokines. Unexpected signaling mechanisms were found to
regulate hepcidin expression, e.g., epidermal growth factor, and
also hepatocyte growth factor, which transduced their effects on
hepcidin through PI3 kinase or MEK/ERK pathways [11].
Interestingly, iron-induced hepcidin expression altered HCV
replication in cultured cells [12].
Therefore, intracellular signaling pathways could regulate
hepatitis virus replication in many ways. More knowledge in this
area will be significant for virus-host interactions and hepatic
injury. Also, cytokines, chemokines and receptors expressed during
host-viral interactions have elicited interest as targets for antiviral
therapies [13].
Here, we reasoned that study of intersections in signaling by
cytokines, e.g., TGF-b, on the one hand, and signaling by small
molecules, e.g., iron, on the other hand, would help clarify
mechanisms in HBV replication. One possibility was that iron
and TGF-b exerted their effects by mechanisms completely
independent of one another. Another possibility was that these
molecules shared common intermediaries but that were
regulated differently.
We used HepG2 2.2.15 cells for our studies since these
express stably transduced HBV genomes with virus replication
and have been suitable for mechanistic studies in vitro [14,15].
This cell line model permitted us to characterize the effects of
TGF-b and iron on HBV replication, to demonstrate activation
of intracellular signaling along TGF-b and BMP pathways, and
to establish potential effector mechanisms in regulation of HBV
replication.
Materials and Methods
Cytokines and Chemicals
We purchased TGF-b (R&D Systems, Minneapolis, MN) and
ferrous sulfate heptahydrate (Sigma Chemical Co., St. Louis,
MO). TGF-b1 receptor kinase inhibitor (TKI), LY-2157299 (Eli
Lilly and Co., Indianapolis, IN) was from Dr. A. Verma at
Einstein. All reagents and chemicals were from Sigma.
Cells
HepG2 2.2.15 cells were derived from HepG2 cells stably
transfected with full-length HBV genomes (14). HepG2 cells were
originally from American Type Culture Collection (ATCC,
Manassas, VA). Cells were cultured in Dulbecco’s Modified
Eagle’s medium with 10% fetal bovine serum, 1% glutamine, 1%
nonessential amino acids, and antibiotics (DMEM). After dose-
ranging studies, we used 20 ng/ml TGF-b, 100 mM iron or
480 ng/ml TKI with cell culture for up to 48 h. For assays, cells
were lysed in 100 mM Tris-HCl, pH 8.0, 0.2% Nonidet P-40 and
protease inhibitors (Calbiochem Cocktail set III, EMD4Bios-
ciences, Darmstadt, Germany). Protein content was measured by
Bradford Reagent (Pierce Research Products, Rockford, IL). To
evaluate cell viability or changes in cell numbers, MTT assays
were performed, as described previously [15].
HBV Assays
To demonstrate hepatitis B core antigen (HBcAg), cell lysates
were resolved in 1.2% native agarose gels, followed by transfer to
nylon membranes (Ambion, Life Technologies, Carlsbad, CA).
HBcAg was detected with anti-HBc (Dako, Carpinteria, CA), as
described previously [14]. For southern blotting, protein-detergent
complexes were precipitated in 2.5 M KCl, viral pellet was
dissolved in Tris-EDTA, and incubated with proteinase K
(Ambion) for 1 h at 37uC. DNA was extracted with phenol-
chloroform and precipitated by ethanol. 20 mg DNAs were
resolved in 1.2% agarose gels and transferred to nylon membranes
(Ambion). To analyze HBV RNA with northern blotting, 20 mg
total cellular RNAs were extracted by Trizol Reagent (Life
Technologies), resolved in 1.0% formaldehyde-agarose, and
transferred to nylon membranes (Ambion). Nonradioactive HBV
probe was prepared with psoralen-Biotin labeling kit (Ambion), as
described by the manufacturer, with full-length HBV DNA from
EcoRI- linearized pCP10 plasmid [16]. Prehybridization and
hybridization of blots was as described previously [15]. Northern
blots were rehybridized with human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe, as described previously [15].
Replicate blots were quantified by densitometry.
TGF-b Receptor Kinase Activity
Cell lysates with 50 mg total proteins each were spotted onto
nylon membranes (Ambion). Blots were probed with mouse anti-
phospho-serine-threonine antibody (Cat#612548, BD Bioscienc-
es, San Diego, CA). Detection used anti-mouse IgG-peroxidase
(Sigma) with chemiluminiscence methods.
Cellular Gene Expression
Total cellular RNAs were isolated with TRIzol Reagent (Life
Technologies). Hepcidin expression was analyzed by quantitative
real-time (RT)-polymerase chain reactions (PCR) with SYBR
Green master mix (Qiagen, Valencia, CA). cDNAs were prepared
with Omniscript RT kit (Qiagen). Hepcidin primers were: sense
59-CTGCAACCCCAGGACAGAG-39 and antisense 59-GGAA-
TAAATAAGGAAGGGAGGGG-39 [17]; GAPDH primers were:
sense 59-GGCCTCCAAGGAGTAAGACC-39, and antisense 59-
AGGGGTCTACATGGCAACTG-39. PCR conditions were: 40
cycles of denaturation at 95uC690 s, annealing at 60uC610 s and
elongation at 72uC620 s. For TGF-b/BMP signaling pathways,
an array with 84 genes was used for qRT-PCR (http://www.
sabiosciences.com/rt_pcr_product/HTML/PAHS-035A.html,
SA Biosciences, Gaithersburg, MD). cDNAs were prepared by
RT
2 First Strand Kit. Each condition was in triplicate. Relative
gene expression was determined by 2 ˆ(-DDCt) method.
Immunostaining
Cells were fixed in methanol at 220uC. Receptor-activated
phosphorylated forms of R-SMAD-2, -3 and -4 were stained with
antibodies (Cat#3101, #9515, #9520, Cell Signaling, Danvers,
MA), followed by detection with Alexa Fluor 633-conjugated goat
anti-rabbit IgG (Molecular Probes, Life Technologies). Nuclei
were counterstained by DAPI.
MicroRNA Studies
Profiles of microRNA expression were obtained in total cellular
RNA samples by microfluidics approach with arrays (Sanger
databases, versions 9.1 and 11.0; LC Sciences, Dallas, TX).
Background was subtracted with regression-based mapping on 5–
25% of lowest intensity data excluding blank spots. Transcripts
with undetectable signals below 36 background, incorporating
spot analysis parameters, were excluded. Later, we excluded
transcripts with ,500 arbitrary signals as these are not identified
by qRT-PCR. RNA hybrids were examined in HBV subtype ayw
(Genbank accession number 665257.1) with miRanda program
using minimal free energy (mfe) below 212 kcal/mol and
miRanda score of over 140 as selection criteria.
Extracellular Factors and HBV Replication
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39276Figure 1. Effects of TGF-b and iron on 2.2.15 cells. Shown are studies with cells cultured in the presence of 20 ng/ml TGF-b or 100 mM iron for
48 h. (A) Hepcidin mRNA expression increased by several-fold in iron-treated cells and not in TGF-b-treated cells. These data are plotted on a natural
log scale in comparison with controls. (B) Serine-threonine kinase activity in cells with increase after TGF-b. This increase in kinase activity was blocked
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commercial source (Dharmacon, Thermo Fisher): 125-a-5p,
UCCCUGAGACCCUUUAACCUGUGA; 151-5p, UCGAG-
GAGCUCACAGUCUAGU. For transfections, cells were incu-
bated for 6 h with 50–200 nM of oligonucleotides in lipofectamine
(Invitrogen). Transfection efficiency was monitored with 100 nM
of Silencer Cy3-labeled Negative Control #1 siRNA (AM4621,
Ambion). Iron or TGF-b were added to cells 12 h after miRNA
transfections. Cells were cultured with Iron or TGF-b for 48 h
before analysis of HBV replication.
Statistical Methods
Data are shown as means 6 standard errors. T-tests or analysis
of variance (ANOVA) with Turkey’s multiple comparisons test
were used with Prism 5 (GraphPAD 5.0, San Diego, CA). P values
,0.05 were taken as significant. Critical studies were repeated 2–4
times.
Results
Iron Increased and TGF-b Decreased HBV Replication in
2.2.15 Cells
After initial dose-response studies, we chose to treat cells with
100 mM iron or 20 ng/ml TGF-b for 48 h. In response to TGF-b,
cell proliferation decreased slightly with MTT utilization of
8769% versus 100% in untreated controls, but this was not
statistically significant. By contrast, in response to iron, cell
proliferation increased slightly with MTT utilization of 11866%
versus 100% in untreated controls, which was also not statistically
significant.
in cells treated simultaneously with TKI. The chart on the right shows results of densitometric scanning in replicates. (C) Native agarose gel showing
HBcAg expression, along with densitometric scanning of bands on right. Iron increased and TGF-b decreased HBV replication. (D) Southern blot of
native agarose gel confirming changes in HBcAg-associated HBV DNA with chart on right showing densitometric quantitation of bands. (E) Northern
blot of HBV mRNA expression with 3.5, 2.4 and 2.1 Kb HBV transcripts as indicated. (F) Southern blot of DNA from cell lysates showing relaxed-circular
(RC), single-stranded (SS) and intermediate replicative forms of HBV DNA. Taken together, these results confirmed that cells were responsive to iron
and TGF-b with the former increasing and the latter decreasing HBV replication.
doi:10.1371/journal.pone.0039276.g001
Figure 2. Mapping of changes in TGF-b/BMP signaling. Shows gene expression changes in 2.2.15 cells treated by 20 ng/ml TGF-b for 48 h
versus untreated controls. Changes were mapped with curated pathways in Ingenuity Pathway Analysis. Genes with increased expression are shown
in red color and genes with decreased expression are shown in blue relative to untreated control cells.
doi:10.1371/journal.pone.0039276.g002
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iron and TGF-b. In iron-treated cells, hepcidin mRNA expression
increased by up to 360-fold, but this was unchanged in TGF-b-
treated cells, p,0.05 (Fig. 1A). In TGF-b-treated cells, activity of
TGF-b receptor serine-threonine kinase increased by up to 4-fold,
p,0.05, and was blocked by TGF-b receptor kinase inhibitor
(TKI) (Fig. 1B). Native agarose gel assays, including southern
blotting of these gels, indicated iron increased HBV replication by
20–40% (Fig. 1C, 1D). By contrast, TGF-b exerted an effect
opposite to iron, since HBV replication decreased by 10–30% in
TGF-b-treated cells. Northern and southern analysis confirmed
these opposite effects of iron and TGF-b on HBV RNA and DNA
expression in 2.2.15 cells (Fig. 1E, 1F).
Table 1. Fold increase in TGF-b/BMP pathway gene expression versus untreated cells (NC=no change).
Gene Groups Gene Gene name Iron TGF-b
TGF-b Superfamily
Cytokines
LEFTY1 Left-right determination factor 1 NC 339
NODAL Nodal homolog (mouse) NC 40
LTBP2 Latent transforming growth factor beta binding protein 2 NC 30
TGFB2 Transforming growth factor, beta 2 NC 21
TGFB1 Transforming growth factor, beta 1 NC 13
INHA Inhibin, alpha NC 11
INHBA Inhibin, beta A NC 5
BMP1 Bone morphogenetic protein 1 NC 5
LTBP1 Latent transforming growth factor beta binding protein 1 NC 4
INHBB Inhibin, beta B NC 3
TGFB3 Transforming growth factor, beta 3 NC 3
Receptors TGFB1I1 Transforming growth factor beta 1 induced transcript 1 NC 10
BMPR2 Bone morphogenetic protein receptor, type II NC 8
ACVR1 Activin A receptor, type I NC 6
TGFBR1 Transforming growth factor, beta receptor 1 NC 5
BMPR1A Bone morphogenetic protein receptor, type IA NC 2
SMADs and Target
Genes
JUNB Jun B proto-oncogene NC 43
PDGFB Platelet-derived growth factor beta polypeptide NC 16
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) NC 26
COL1A1 Collagen, type I, alpha 1 NC 14
ENG Endoglin NC 12
IGF1 Insulin-like growth factor 1 (somatomedin C) NC 11
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 NC 11
FST Follistatin NC 7
SOX4 SRY (sex determining region Y)-box 4 NC 6
DLX2 Distal-less homeobox 2 NC 6
TGFBI Transforming growth factor, beta-induced, 68 kDa NC 6
BAMBI BMP and activin membrane-bound inhibitor homolog NC 5
JUN Jun proto-oncogene NC 5
RUNX1 Runt-related transcription factor 1 NC 4
SMAD3 SMAD family member 3 NC 4
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) NC 4
TGIF1 TGFB-induced factor homeobox 1 NC 4
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 NC 3
FOS FBJ murine osteosarcoma viral oncogene homolog NC 3
ID1 Inhibitor of DNA binding 1 NC 3
ITGB5 Integrin, beta 5 NC 2
NBL1 Neuroblastoma, suppression of tumorigenicity 1 NC 2
SMAD5 SMAD family member 5 NC 2
NBL1 Neuroblastoma, suppression of tumorigenicity 1 NC 2
doi:10.1371/journal.pone.0039276.t001
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39276Figure 3. Regulation of SMAD expression in cells. Cells were cultured with 20 ng/ml TGF-b, 100 mM iron, or 100 mM iron plus 480 ng/ml TKI for
48 h. Immunostaining of cultured cells is shown in representative images for phosphorylated SMAD-2 (A), SMAD-3 (B) and SMAD-4 (C) (red color with
DAPI counterstaining of nuclei in blue color). Morphometric analysis of larger samples of cells is given in accompanying charts. TGF-b increased
expression of SMAD-2 and SMAD-4 but not SMAD-3. By contrast, iron had no effect on expression of SMAD-2 or SMAD-3. However, iron increased
SMAD-4 expression, which was partly blocked by TKI. These results indicated differences in the nature of intracellular signaling in cells treated with
iron or TGF-b although activation of SMAD-4 by both iron and TGF-b indicated confluence of TGF-b/BMP signaling in these conditions. This was
emphasized by lowering of SMAD-4 expression in cells treated with iron plus TKI. Orig. mag., x630.
doi:10.1371/journal.pone.0039276.g003
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Pathways
In iron-treated 2.2.15 cells, expression of genes in TGF-b/BMP
signaling pathways were not different from control untreated cells.
However, TGF-b-treated cells showed marked differences in gene
expression (Table 1). We found multiple cytokines in TGF-b
superfamily were expressed at higher levels, including left-right
determination factor (339-fold) and Nodal (40-fold), which
regulate embryonic development. Expression of several cytokines
increased, including TGF-b1 (13-fold), TGF-b2 (21-fold), and
TGF-b3 (3-fold), BMP1 (5-fold), latent TGF-b-binding proteins
(LTBP)-1 (4-fold) and -2 (30-fold), as well as inhibin (INH)-A (11-
fold), -BA (5-fold), and -BB (3-fold). Similarly, expression increased
of TGF-b and related receptors, including TGF-bR1 (5-fold),
TGF-b1-induced transcript 1 (10-fold), BMPR1A (2-fold), BMPR2
(8-fold), and activin receptor 1 (6-fold). Moreover, increased
expression was noted of TGF-b transducers, i.e., SMAD-3 (4-fold),
SMAD-5 (2-fold), TGF-b-induced (6-fold), and TGF-b-induced
factor homeobox 1 (4-fold). Several cell proliferation regulators
were expressed more, i.e., Jun (5-fold), JunB (43-fold), Fos (3-fold),
p15 (CDKN2B) (26-fold), p21 (CDKN1A) (4-fold), insulin-like
growth factor-I (11-fold), and platelet-derived growth factor B (16-
fold). Extracellular matrix genes were expressed more, e.g.,
collagen, type 1, al (14-fold) and integrin bV (2-fold), which was
consistent with fibrogenic-type changes in TGF-b-treated cells. To
visualize these gene relationships, we mapped canonical TGF-b/
BMP pathways (Fig. 2).
We did not determine the effects of TKI on TGF-b-induced
gene expression because it successfully blocked TGF-b response in
2.2.15 cells. However, we studied whether TKI would alter
cellular responses to iron. In cells treated by iron plus TKI, we
found no increases in expression of TGF-b superfamily cytokines
or receptors, although expression of Nodal, INHA and LTBP4
declined by 2–3-fold.
SMAD Protein Expression in Cells
We immunostained cells for phosphorylated SMAD-2, -3 and
SMAD-4 proteins to confirm changes in TGF-b/BMP signaling.
In untreated cells, SMAD-2 was observed occasionally in cell
cytoplasm (Fig. 3A). Iron did not alter SMAD-2 expression. This
was different in TGF-b-treated cells, since SMAD-2 was now
expressed in 82% of cells, p,0.05, along with translocation of the
protein in many cells to nuclei. By contrast, iron plus TKI did not
affect SMAD-2 expression. SMAD-3 was expressed well under
basal conditions and also in iron- or TGF-b-treated cells (Fig. 3B).
Expression of SMAD-4 changed prominently with significant
increases from basal levels in iron- (53%) or TGF-b-treated cells
(57%), p,0.05. In cells treated with iron plus TKI, increases in
SMAD-4 expression were limited (Fig. 3C). These findings
indicated that TGF-b signaling contributed to SMAD-4 expres-
Table 2. Changes in microRNA expression versus control
untreated cells.
Downregulated Upregulated
MicroRNA Log2 fold-change MicroRNA Log2 fold-change
Iron-treated
hsa-miR-106a 28.38 hsa-let-7a 2.66
hsa-miR-1246 26.80 hsa-let-7b 7.20
hsa-miR-125a-5p 24.06 hsa-let-7c 6.33
hsa-miR-1275 21.69 hsa-let-7d 3.6
hsa-miR-128 22.74 hsa-let-7e 2.41
hsa-miR-148a 27.64 hsa-let-7f 2.66
hsa-miR-151-3p 21.79 hsa-let-7g 1.58
hsa-miR-151-5p 22.06 hsa-let-7i 2.51
hsa-miR-17 27.64 hsa-miR-1224-5p 4.17
hsa-miR-18a 27.16 hsa-miR-1228* 5.51
hsa-miR-192 24.64 hsa-miR-1268 2.49
hsa-miR-194 23.09 hsa-miR-1305 3.93
hsa-miR-200b 25.64 hsa-miR-130a 2.58
hsa-miR-20a 210.70 hsa-miR-15b 1.14
hsa-miR-20b 28.38 hsa-miR-182 1.38
hsa-miR-21 22.18 hsa-miR-183 2.04
hsa-miR-224 28.97 hsa-miR-188-5p 4.10
hsa-miR-26a 21.79 hsa-miR-195 5.68
hsa-miR-320a 22.64 hsa-miR-206 4.54
hsa-miR-320b 22.18 hsa-miR-210 3.42
hsa-miR-320c 22.40 hsa-miR-22 2.23
hsa-miR-320d 22.47 hsa-miR-23a 1.07
hsa-miR-361-5p 21.40 hsa-miR-29c 4.09
hsa-miR-423-5p 21.40 hsa-miR-300 3.97
hsa-miR-454 27.16 hsa-miR-30b 1.63
hsa-miR-455-3p 25.06 hsa-miR-30c 2.20
hsa-miR-605 25.64 hsa-miR-31 8.58
hsa-miR-638 21.12 hsa-miR-34c-3p 4.43
hsa-miR-663 23.47 hsa-miR-568 9.87
hsa-miR-720 22.06 hsa-miR-574-3p 6.61
hsa-miR-877 25.06 hsa-miR-574-5p 4.07
hsa-miR-92a 25.06 hsa-miR-595 5.29
hsa-miR-92b 29.97 hsa-miR-601 5.88
hsa-miR-765 4.47
hsa-miR-98 5.05
hsa-miR-99a 6.41
TGF-b-treated
hsa-miR-20b 21.29 hsa-let-7a 1.38
hsa-miR-221 21.25 hsa-let-7d 1.43
hsa-miR-605 24.64 hsa-let-7e 2
hsa-miR-638 21.40 hsa-miR-125a-5p 2.87
hsa-miR-663 22.06 hsa-miR-146a 2.72
hsa-miR-720 22.40 hsa-miR-21 1.14
hsa-miR-23a 1.20
hsa-miR-23b 1.14
hsa-miR-30c 1.89
Table 2. Cont.
Downregulated Upregulated
MicroRNA Log2 fold-change MicroRNA Log2 fold-change
hsa-miR-483-5p 1.38
hsa-miR-574-5p 2.23
hsa-miR-99b 1.63
doi:10.1371/journal.pone.0039276.t002
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was largely in cytoplasm under all conditions.
Iron or TGF-b Altered Cellular miRNA Expression
To identify potential transducers of TGF-b/BMP signaling in
HBV replication, we analyzed miRNA expression. We chose to
study this mechanism because expression of HBV genes should not
have been directly regulated by SMADs activated by TGF-b/
BMP signaling. On the other hand, SMADs can regulate
expression of cellular miRNA, which, in turn, could have altered
HBV replication (see below).
In iron-treated cells, from a total of 814 miRNA, 33 and 36
miRNA were downregulated or upregulated, respectively, versus
untreated control cells (Table 2). Decreased miRNA expression
ranged from Log2 fold of 21.12 (hsa-miR-638) to 210.70 (hsa-
miR-20a). Increased miRNA expression ranged from Log2 fold of
1.07 (hsa-miR-23a) to 9.87 (hsa-miR-568). In TGF-b-treated cells,
changes were less prominent, with downregulation of 6 and
upregulation of 12 miRNA versus untreated control cells. The
Table 3. Properties of miRNA capable of targeting HBV.
miRNA
HBV target (nt)
and (HBV gene)
Mfe
(kcal/mol)
miRanda
score Sequence alignment
hsa-let-7a 90–111
(P/S)
218.6 153 miRNA
39 UUGAUAUGUUGGAUGAUGGAGU 59
59 CCCTGTT CCGACTACT GCCTCT 39 target
hsa-let-7d 91–111
(P/S)
219.3 151 miRNA
39 UGAUACGUUGGAUGAUGGAGA 59
59 CCTG TTCCGACTACTG CCTCT 39 target
3075–3104
(P/S)
215.3 146 59 miRNA
39 UGAUACG–––––-UU––––GGAUGAUGGAGA
59 ACTTT GCCAGCAAATCCGCCTCCTGCCTCC 39 target
hsa-let-7e 3084–3104
(P/S)
220.4 154 miRNA
39 UGAUAUGUUGGAGGAUGGAGU 59
59 GCAAATCCGCC TCCTGCC TCC 39 target
91–111
(P/S)
215.9 146 miRNA
39 UGAUAUGUUGGAGGAUGGAGU 59
59 CCTG TTCCGACTACTG CCTCT 39 target
hsa-miR-106a 1568–1590
(P/X)
219 151 miRNA
39 CGAUGGAC–GUGACAUUCGUGAAAA 59
59 TCT GCCTGACCTTGT––-GCACTTCG 39 target
hsa-miR-125a-5p 1451–1472
(P/X)
219.36 151 miRNA
39 GUGUCCAAUUUCCCAGAGUCCCU 59
59 CGC–GGACGACCCGTCTCGGGGT 39 target
3038–3065 (P/S/X) 218.4 161 59 miRNA
39 GUGUCCAA UUUC––––––-CCAGAGUCCCU
59 TTT GGGGTGGAGCCCTCAGG–CTCAGGGC 39 target
hsa-miR-148a 130–154
(P/X)
215.4 140 miRNA
39 UGUUUCAAGACAUC––––-ACGUGACU 59
59 TCGAGGAT–TGGGGACCCTGCGCTGA 39 target
hsa-miR-151 231–254
(P/S)
212.2 144 59miRNA
39 GGAGU–UCCU––CGAAGUCAGAUCA
59 CC TCACAATACCGC–AGAGTCTAGA 39 target
hsa-miR-17 1568–1590
(P/X)
219.4 151 miRNA
39 UGAUGGAC-GUGACAUUCGUGAAAC 59
59 TCTGCCTGACCTTGT––GCACTTCG 39 target
hsa-miR-18a 1514–1535
(P/X)
214.2 144 miRNA
39 AUAGACGUGAUCUACGUGGAAU 59
59 ACCGACCACGGGGCGCACCTCT 39 target
hsa-miR-20a 1569–1590
(P/X)
216.7 149 miRNA
39 GAUGGACGUGAUAUUCGUGAAAU 59
59 CTGCCTG–-ACCTTGTGCACTTCG 39 target
hsa-miR-20b 1569–1590
(P/X)
219.6 155 miRNA
39 GAUGGACGUGAUACUCGUGAAAC 59
59 CTGCCTG–-ACCTTGTGCACTT CG 39 target
hsa-miR-224 281–304
(P/X)
220.3 144 miRNA
39 AUUUGCCUUGGUGAU–CACUGAAC 59
59 TAGGGGGAACTACCGTGTGTCTTG 39 target
hsa-miR-483 1726–1744 (X) 221.4 145 miRNA
39 UCUUCUGCCCUCCUCUCCUCACU 59
59 TAAAGACTGG––––GAGGAGTTG 39 target
P, polymerase, S, surface, and X, X open reading frames of HBV.
doi:10.1371/journal.pone.0039276.t003
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39276Figure 4. Regulation of HBV replication by agarose gel analysis in cells treated with miRNA. For these studies, 2.2.15 cells were
transfected with miRNA mimics or miRNA antagonists followed by administration to transduced cells of either 20 ng/ml TGF-b or 100 mM iron for
48 h. (A) Changes in iron-treated cells are shown after expression of miR-125a-5p or -151-5p mimics. These mimics dose-dependently decreased HBV
replication in iron-treated cells. (B) Changes in TGF-b-treated cells are shown after expression of miR-125a-5p and miR-151-5p antagonists. These
antagonists dose-dependently reversed TGF-b-induced inhibition of HBV replication. This substantiated the role of intracellular miRNA in regulation
of HBV replication by iron or TGF-b.
doi:10.1371/journal.pone.0039276.g004
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39276level of miRNA expression change was also lower, since Log2 fold
decreases ranged from 21.25 (hsa-miR-221) to 24.64 (hsa-miR-
605) and Log2 fold increases ranged from 1.14 (hsa-miR-23b) to
2.87 (hsa-miR-125a-5p).
Of 6 downregulated miRNA in TGF-b-treated cells, 5 were
also downregulated in iron-treated cells: hsa-miR-20b, -605, -
638, 663, and -720. Expression of hsa-miR-221was unchanged
in iron-treated cells. Expression of 12 miRNA upregulated in
TGF-b-treated cells both resembled and differed in iron-treated
cells: 6 miRNA were similarly upregulated, hsa-miR-7a, -7d, -
7e, -23a, -30c, and -574-5p; 2 miRNA were downregulated,
hsa-miR-125a-5p and -21; and expression of 4 miRNA was
unchanged, hsa-miR-146a, -23b, -483-5p, and -99b.
The counter-regulation in TGF-b- and iron-treated cells of hsa-
miR-125a-5p and -21 was of interest, since these, and other
miRNA, may have contributed in HBV replication. RNA hybrid
analysis of miRNA listed in Table 2 identified alignment of 13
miRNA with HBV domains (Table 3): hsa-let-7a, -7d, -7e, -106a,
-125a-5p, -148a, -151, -17, -18a, -20a, -20b, -224, and -483.
Regulation of HBV Replication by miRNA Sequences
We selected miR-125a-5p and -151-5p for analyzing their
effects on HBV replication. These miRNA are considered to
interfere with HBV replication [18,19]. In response to miR-125a-
5p and -151-5p mimics, iron-induced HBV replication declined in
dose-dependent fashion by up to 23% and 45%, respectively,
p,0.05 (Fig. 4A). Expression of miR-125a-5p and -151-5p
antagomirs did not affect iron-induced HBV replication. Treat-
ment of cells with antagonists of miR-125a-5p did not reverse
TGF-b-induced suppression of HBV replication (Fig. 4B). How-
ever, antagonist of miR-151-5p reversed TGF-b-induced suppres-
sion of HBV replication. Mimics of miR-125a-5p and -151-5p did
not affect TGF-b-induced inhibition of HBV replication. This
confirmed that individual miRNAs were capable of altering HBV
replication.
Discussion
These studies established 2.2.15 cells were appropriately
responsive to iron and TGF-b. In case of iron, this was evidenced
by greater hepcidin expression, which is transcriptionally regulated
via BMP signaling [20], and requires the cofactors, hemojuvelin
and neogenin [21]. Responsiveness to TGF-b was evidenced by
receptor kinase activity blocked by TKI. TGF-b changed
expression of TGF-b/BMP pathway genes and targets, along
with increases in phosphorylated SMAD-2, -3 and -4, as was
anticipated. Iron did not alter expression of TGF-b/BMP pathway
genes at mRNA levels but SMAD-4 expression linked TGF-b and
BMP signaling pathways in iron-treated cells [7]. Despite
association of iron with unfavorable outcomes in people with
HBV [8,9], underlying mechanisms directing HBV replication
were unknown. Previously, depletion of iron in HepG2 cells
decreased HBV production [22]. This was consistent with
increased HBV replication here in iron-treated HepG2 cells. We
came across another study of TGF-b and HBV replication in
HepG2 cells [6], where TGF-b decreased HBV replication,
similar to our results. However, underlying mechanisms in how
TGF-b directed HBV replication were unknown.
The role of TGF-b-induced SMADs in transcriptional
controls was one possibility. Upon ligand-binding, the constitu-
tionally active type II TGF-b receptor phosphorylates type I
TGF-b receptor, followed by recruitment of SMAD-2 and -3,
which complex with SMAD-4 for transcriptional activation [7].
BMP receptors activate SMAD-1, -5 and -8, which too complex
with SMAD-4 for transcriptional activation. Therefore, SMAD-
4 connects TGF-b and BMP signaling. Under some situations,
TGF-b- or BMP-specific SMADs may be simultaneously
activated [23]. We considered that cellular miRNAs could have
served intermediary roles in transducing the effects of TGF-b/
BMP signaling on HBV replication. Recently, cellular miRNAs
attracted much attention as ubiquitous antiviral regulators,
including for HBV [18,19,24]. miRNAs negatively regulate gene
expression by sequence-specific binding of mRNAs followed by
mRNA degradation or interference in mRNA translation. The
identification of promoter sites in genomic regions encoding
miRNAs, including SMAD-binding elements (SBE) [25,26], was
noteworthy to us. Multiple miRNA were shown to contain SBE,
e.g., hsa-let-7a, -7b, -7c, -7d, -7e, -7f, -21, -23b, etc. [26]. These
miRNA were expressed in iron- or TGF-b-treated cells in our
study. However, miRNA expression was different in iron- or
TGF-b-treated cells. This difference was not explained by
SMADs alone. Also, this difference was not explained by
transcription factors regulating iron homeostasis, e.g., hemoju-
velin or neogenin, since these are not incriminated in miRNA
transcription.
Another explanation was provided by mechanisms in processing
of pri-miRNA to mature miRNA [27]. All canonical pri-miRNA
undergo sequential cleavages in nucleus and cytoplasm by Dicer or
Drosha RNAse III enzymes for maturation. Drosha requires the
RNA-binding protein, DiGeorge Critical Region 8 (DGCR8), for
pre-miRNA cleavage. Recently, heme was identified as a
constituent of Drosha-DGCR8 complex, with the ionic state of
heme-bound iron determining whether the complex will be
capable of pri-miRNA cleavage [27]. In the ferric state, Drosha-
DGCR8-heme complex was highly stable and actively processed
pri-miRNA to mature miRNA. By contrast, transition to ferrous
state abolished pri-miRNA cleavage by Drosha-DGCR8-heme
complex. Thus, alterations in intracellular environment, leading to
ferric or ferrous state of iron in Drosha-DGCR8-heme complex,
likely accounted for differential miRNA expression in iron- or
TGF-b-treated cells.
The nature of miRNA-based host–virus interactions is evolving
at present. Several anti-HBV miRNA were previously reported,
e.g., hsa-miR-125-5p, -125-b, -151-5p, -199a-3p, -122, etc.,
including targets in polymerase, core, surface or X genes
(15,18,19,28,29). In chronic hepatitis B and HBV-associated
HCC, several miRNA were also found in blood, including hsa-
miR-7, - 196b, -433, -511, with targets in polymerase or surface
genes; hsa-miR-205, targeting X gene; and hsa-miR-345, targeting
HBV preC gene [30]. Several of these were present in our list of
miRNA expressed differentially in iron- or TGF-b-treated cells,
whereas other miRNAs aligning with HBV sequences in our list
had previously not been recognized.
Our miRNA expression studies showing modulation of the
effects of iron- or TGF-b on HBV replication were instructive. As
hsa-miR-125a-5p and -151-5p mimics prevented iron-induced
increases in HBV replication, while their antagonists prevented
TGF-b-induced decreases in HBV replication, this established
miRNA were the principal intracellular effectors of TGF-b/BMP
signaling.
Differentially expressed miRNA in iron-treated cells, and for
that matter, TGF-b-treated cells, target genes widely, including
pathways in cell stress and toxicity, cell proliferation, immune
responses, metabolism, etc., which will be relevant for chronic
hepatitis. Iron plays major roles in oxidative stress and
cytotoxicity, which coupled with perturbations in HBV replica-
tion, may alter natural history of hepatitis. TGF-b is especially
significant for hepatic growth control and also for fibrosis.
Extracellular Factors and HBV Replication
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39276Therefore, regulation of miRNA expression by iron and TGF-b
will provide opportunities for understanding disease mechanisms
in HBV-related liver injury and fibrosis. Moreover, mechanisms
directing antiviral miRNA expression in iron- or TGF-b-treated
cells should be helpful for drug development, according to
considerations discussed previously by other investigators [27].
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